Unicycive Therapeutics

IPO

Home - Unicycive

Public · Mountain View, United States · Founded 2016 · $134.0M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$134.0M
Last Round
$50.0M Corporate RoundMar 2024
Rounds
6
Type
Public

About

Unicycive Therapeutics is a biotechnology company founded in 2016 to accelerate kidney-disease innovation by identifying overlooked assets and developing them into therapies. Its pipeline includes oxylanthanum carbonate (OLC) for hyperphosphatemia in chronic kidney disease patients on dialysis, whose New Drug Application the FDA accepted in 2024, and UNI-494, which completed a Phase 1 study in healthy volunteers. The company, listed on NASDAQ as UNCY, focuses on closing urgent gaps in kidney care by moving undervalued technologies through clinical development with speed and efficiency for patients and providers.

Summary

Unicycive Therapeutics is a Biotech company based in Mountain View, United States, founded in 2016. It has raised $134.0M in total across 6 rounds, most recently a $50.0M Corporate Round round in Mar 2024.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundMar 2024
$50.0M

Sign up to see all 7 rounds

Seed through Corporate Round — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Unicycive Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/unicycive-therapeutics"><img src="https://indexed.vc/api/badge/company/unicycive-therapeutics" alt="Unicycive Therapeutics on Indexed.vc" width="260" height="76" /></a>